Form 4: Crescent Biopharma Director Receives Stock Option Grant

Director Susan Moran was granted 11,050 stock options in Crescent Biopharma, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Susan Moran received a grant of 11,050 stock options on June 2, 2026.
• The options have an exercise price of $17.01 per share.
• The options vest in full on the earlier of June 2, 2027, or the date of the next annual shareholder meeting, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard corporate governance and compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the director's continued service to the company.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to attract and retain board talent, aligning leadership incentives with corporate performance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biopharmaceutical companies.
• The one-year cliff vesting period is a standard industry benchmark for director equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 2, 2027, or the next annual meeting.

Key Dates

Keywords

Crescent Biopharma, CBIO, Director Compensation, Stock Options, Insider Transaction, Form 4